Is Pfizer a good stock?
52 rows · The Pfizer 52-week high stock price is 61.71, which is 16.2% above the current share price. The Pfizer 52-week low stock price is 37.96, which is 28.5% below the current share price. The average Pfizer stock price for the last 52 weeks is 46.82.
Is Pfizer publicly traded?
102 rows · Discover historical prices for PFE stock on Yahoo Finance. View daily, weekly or monthly format back to when Pfizer Inc. stock was issued. ... Pfizer Inc. (PFE) NYSE - Nasdaq Real Time Price ...
What is wrong with Pfizer stock price?
Pharmaceutical mega-titan Pfizer ( PFE -0.02% ) lost an eye-catching 10.2% of its value over the course of 2019, according to data from S&P Global Market Intelligence. Investors avoided this top ...
Why is Pfizer stock falling?
Find the latest historical data for Pfizer, Inc. Common Stock (PFE) at Nasdaq.com.
What was Pfizer stock worth in 2019?
39.9501Compare PFE With Other StocksPfizer Historical Annual Stock Price DataYearAverage Stock PriceAnnual % Change201939.9501-10.24%201839.156520.51%201734.074511.51%47 more rows
What was Pfizer stock price in 1998?
PFE - Pfizer Inc.DateOpenLowNov 04, 19980.060089 DividendNov 01, 199834.0632.89Oct 01, 199832.7327.20Sep 01, 199829.6529.1081 more rows
Why is Pfizer stock down 2021?
Pfizer CEO Albert Bourla talks. Pfizer shares dropped sharply after the company's 2022 sales guidance appeared to fall short of expectations. The guidance that Pfizer (ticker: PFE) presented, however, doesn't take into account future sales of Pfizer's Covid-19 vaccine and antiviral, but only sales already made.Feb 9, 2022
Is Pfizer a good stock for 2021?
This puts the stock at 20.75% beneath its 52-week high, as it has been caught in the downdraft that has affected the entire stock market since late 2021. Even with its late-2021 selloff, however, Pfizer had a great 2021, up 60.42% on the back of coronavirus vaccine sales and general stock market strength.Feb 21, 2022
How much did Pfizer stock go up after Viagra?
Positive news about Viagra's sales drove Pfizer's stock price to a record $113.75 in trading on the New York Stock Exchange yesterday, though by the close the stock had fallen a bit, to $113.37 1/2. That was a jump of nearly 8 percent from Friday's close.
What was Pfizer worth in 2018?
$159.422BPfizer total assets for 2018 were $159.422B, a 7.2% decline from 2017.Jan 22, 2022
Is Pfizer a buy Zacks?
How good is it? See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.93%2Buy18.44%3Hold9.99%4Sell5.61%2 more rows
Is Pfizer a good company to invest?
For example, Pfizer is considered a large-cap value company, suggesting it may not see the rapid growth of, say, a relatively new tech company. However, Pfizer offers a strong dividend that has increased since mid-2009, and in 2020, its stock price was less volatile than most of its competitors.
Can I buy Pfizer stock?
To buy Pfizer stock, you need to open a brokerage account. A broker serves as an intermediary between you and the stock market, facilitating the purchase and sales of securities like stocks and bonds. If you don't have a brokerage account yet, look for ones that have no trading fees and low investment minimums.Mar 21, 2022
Is Pfizer a buy in 2022?
We now estimate Pfizer's Valuation to be $63 per share, which is 23% above the current market price of $51, implying that the current dip in PFE stock is a good buying opportunity for higher gains in the long term. This represents a P/E ratio of 9x based on our forecast of $6.90 EPS in 2022.Feb 11, 2022
Will Pfizer raise its dividend?
(NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.40 for the first-quarter 2022 dividend, payable March 4, 2022, to holders of the Common Stock of record at the close of business on January 28, 2022.Dec 10, 2021
Who owns Pfizer stock?
The Vanguard Group, Inc.Top 10 Owners of Pfizer IncStockholderStakeShares ownedThe Vanguard Group, Inc.7.83%442,214,512SSgA Funds Management, Inc.5.04%284,816,832BlackRock Fund Advisors4.83%272,567,316Capital Research & Management Co....4.19%236,858,4166 more rows
Did the drugmaker's planned metamorphosis fail to impress investors?
Is the pharmaceutical giant a growth play?
The drugmaker's planned metamorph osis failed to impress investors , but that wasn't its only headwind.
Does Pfizer need to change course?
The answer is a resounding yes. The fact of the matter is that this pharmaceutical giant should be a far more compelling growth play than it has been in years past, thanks to management's decision to finally execute a much-needed split.
What was Pfizer's profit in 2018?
Wall Street rarely likes major shake-ups, especially when they are undertaken by industry stalwarts like Pfizer. Pfizer, however, clearly needed to change course. Despite the drugmaker's successful pivot to oncology as a main growth driver, it simply hasn't been able to generate healthy levels of top-line growth on a consistent basis due to an avalanche of patent expiries. The spin-off of its generic drug business should immediately remedy that fundamental problem. In fact, management expects the company's revenues to rise by an average of 6% annually for the period from 2021 through 2025.
What is gross profit?
Pfizer annual gross profit for 2018 was $31.838B, a 22.94% decline from 2017. Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals.
C-suite perspective
Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services. Pfizer gross profit for the quarter ending March 31, 2021 was $10.371B, a 27.36% increase year-over-year.
ADDITIONAL Pfizer Q4 EARNINGS REPORT HIGHLIGHTS
"2019 was a busy year, highlighted by solid financial performance, shareholder-friendly capital allocation, the strengthening of our pipeline as well as the formation of the Consumer Healthcare JV with GSK," Dr. Albert Bourla, chief executive officer of Pfizer, said in a statement.
